Publications by authors named "Santosh Pattnayak"
Article Synopsis
- This study investigates the safety and effectiveness of whole-body hypothermia in neonates who have experienced mild hypoxic-ischemic encephalopathy (HIE), as existing data mainly focuses on cases of more severe illness.* -
- Conducted as a randomized clinical trial across six neonatal intensive care units in the UK and Italy, 101 eligible neonates were assigned to either normothermia or different durations of hypothermia (48 or 72 hours) based on their age after birth.* -
- The study primarily measures the concentration of thalamic N-acetyl aspartate through MRI to assess the impact of hypothermia on brain health, revealing specific outcomes in the treatment groups.*
Article Synopsis
- - The study aimed to evaluate two antiseptic methods for skin disinfection before inserting central venous catheters in preterm infants, as catheter-related sepsis (CRS) poses serious health risks.
- - Conducted across two neonatal intensive care units in the UK, the feasibility study involved 116 preterm babies and assessed various outcomes such as catheter colonisation, sepsis rates, and recruitment success.
- - Results showed a low catheter colonisation rate of 5.2% and minimal incidents of sepsis, indicating that while a larger trial is possible, it may require many participants due to the low event rate.
Background: In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.
Methods: We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy.
Background: Variable responses to hypothermic neuroprotection are related to the clinical heterogeneity of encephalopathic babies; hence better disease stratification may facilitate the development of individualized neuroprotective therapies.
Objectives: We examined if whole blood gene expression analysis can identify specific transcriptome profiles in neonatal encephalopathy.
Material And Methods: We performed next-generation sequencing on whole blood RNA from 12 babies with neonatal encephalopathy and 6 time-matched healthy term babies.
Epidemiology of UK neonatal infections: the neonIN infection surveillance network.
Arch Dis Child Fetal Neonatal Ed
November 2018
Objective: To describe the epidemiology of neonatal infection over the past decade in UK neonatal units.
Design: Retrospective analysis of prospectively collected infection surveillance network data from 2005 to 2014.
Setting: 30 neonatal units in the UK.
Antimicrobial resistance in UK neonatal units: neonIN infection surveillance network.
Arch Dis Child Fetal Neonatal Ed
September 2018
Objective: To define the susceptibilities of the common causative pathogens of neonatal sepsis in the UK.
Design: Retrospective analysis of the prospectively collected neonIN infection surveillance network data between 2005 and 2014.
Setting: 30 neonatal units in the UK.
Objective: To define the clinical features and outcomes of neonatal listeriosis, and identify the maternal risk factors to seek scope for improvement.
Methods: Neonatal listeriosis was identified prospectively from a United Kingdom neonatal infection surveillance network (neonIN) between 2004 and 2014. The participating neonatal units completed a study-specific proforma.
Introduction: Despite cooling, adverse outcomes are seen in up to half of the surviving infants after neonatal encephalopathy. A number of novel adjunct drug therapies with cooling have been shown to be highly neuroprotective in animal studies, and are currently awaiting clinical translation. Rigorous evaluation of these therapies in phase II trials using surrogate MR biomarkers may speed up their bench to bedside translation.
View Article and Find Full Text PDF